RS-2025-25455212

Development of a triple-function improved anti-GD2 CAR natural killer cell-based treatment for recurrent glioblastoma derived from induced pluripotent stem cells

Vigencell

ONCOLOGY | **Preclinical**

Product Type	Cell therapies
Indication	Glioblastoma
Target	GD2 + Glioblastoma
MoA(Mechanism of Action)	1. CXCL-8 gradients from tumor cells activate CXCR2 on VC-302, guiding its migration toward the tumor. 2. VC-302 targets $GD2^{+}$ glioblastoma via GD2-CAR, and upon tumor recognition, induces granzyme- and perforin-mediated cytolytic killing of glioblastoma cells.
Competitiveness	1. VC-302 vs. Temozolomide / Bevacizumab : Higher tumor targeting and stronger cytolytic activity. 2. VC-302 vs. Allo NK / T Cell Therapies : Enhanced efficacy via multi-gene expression and GD2-CAR design. 3. VC-302 vs. Auto NK / T Cell Therapies : Off-the-shelf and cost-effective with superior tumor killing.
Development Stage	Preclinical
Route of Administration	Intratumoral / Intraventricular injection

Any unauthorized distribution or reproduction of this material is strictly prohibited.